Physician profile
Mitchell Abramson
NPI 1417952284
$2,804.54
in general payments reported to CMS, 2019-2025
24 companies · $848 in 2025
The $848 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $131 · 2021: $114 · 2022: $236 · 2023: $410 · 2024: $1,066 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,323 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.62 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $917.14 | 2022-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $397.73 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $334.39 | 2020-2024 | |
| Lilly USA, LLC | $294.70 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $169.33 | 2022-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $122.54 | 2023-2025 | Wegovy |
| Insmed, INC. | $102.84 | 2024-2025 | Arikayce |
| Exact Sciences Corporation | $73.12 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $63.52 | 2023-2024 | Otezla, Repatha |
| Hologic Sales and Service, LLC | $48.47 | 2025 | Thinprep 2000 Processor, Aptima |
| Novartis Pharmaceuticals Corporation | $45.51 | 2024 | |
| Astellas Pharma US INC | $33.51 | 2022-2023 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.05 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.00 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $23.75 | 2024 | Eliquis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $19.14 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.05 | 2025 | Zoryve |
| Amarin Pharma, INC. | $16.26 | 2022 | |
| Acerus Pharmaceuticals Corporation | $15.81 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.86 | 2021 | |
| Hikma Pharmaceuticals USA | $14.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.29 | 2023 | Rexulti |
| Inspire Medical Systems, INC. | $13.88 | 2024 | Inspire |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Abramson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.